Royalty Pharma (RPRX) reported $736 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 30.8%. EPS of $1.15 for the same period compares to $1.56 a year ago.The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of $702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to deter ...